Cybin Inc. (OTCMKTS: CLXPF) is a biotechnology company focused on the research, development and commercialization of psychedelic-based therapeutics for the treatment of mental health and wellness disorders. The company leverages proprietary drug discovery platforms to design novel analogues of psilocybin and other psychoactive compounds. Its programs aim to improve the safety, bioavailability and manufacturability of these molecules while addressing conditions such as depression, anxiety and substance use disorders.
Cybin’s pipeline encompasses several clinical and preclinical stage candidates. Among these are deuterated psilocybin derivatives and next-generation tryptamine-based molecules designed to offer controlled therapeutic effects. The company collaborates with academic and clinical research centers in North America to conduct Phase 1 and early Phase 2 trials, evaluating pharmacokinetics, dosing regimens and safety profiles under regulated frameworks.
Founded in 2019 and headquartered in Toronto, Ontario, Cybin maintains a presence in both Canada and the United States. The leadership team is led by Chief Executive Officer Doug Drysdale, who brings over 25 years of life sciences experience. The company’s board and scientific advisors include experts in psychiatry, medicinal chemistry and regulatory affairs, guiding Cybin’s strategic direction and clinical development efforts.
Cybin is committed to advancing psychedelic medicine through innovative drug development, manufacturing scalability and regulatory engagement. By building an intellectual property portfolio and forging partnerships with contract research organizations and academic institutions, the company aims to deliver new treatment options that address unmet needs in mental health care.
AI Generated. May Contain Errors.
